Section 02 · Monograph
Celecoxib oral solution
Reviewed Nov 2026FDA label
ElyxybNSAID (COX-2)
- Forms
- Sol: 120mg/4.8mL
- Dose
- 120mg once at onset (max 120mg/day)
- MOA
- Selective COX-2 inhibition
Black Box Warning
- Risk of serious cardiovascular thrombotic events (MI, stroke); contraindicated in the setting of CABG surgery
- Risk of serious GI bleeding, ulceration and perforation, which can be fatal
Indications
- Acute treatment of migraine with or without aura in adults (Elyxyb)FDA-labeled
Mechanism of Action
- Selective COX-2 inhibitor reducing prostaglandin-mediated pain and inflammation
Full Dosing
Adult / usual
- 120mg (4.8mL) once at migraine onset; maximum 120mg in 24 hours
- Not for migraine prevention
Contraindications
- Sulfonamide allergy
- Asthma, urticaria or allergic reaction to aspirin or NSAIDs
- Perioperative CABG pain
Drug Interactions
- CYP2C9 inhibitors (fluconazole) raise celecoxib levels
- ACE inhibitors, ARBs and diuretics: reduced effect and renal risk
- Raises lithium levels; bleeding risk with anticoagulants
Adverse Effects
- Dyspepsia, nausea
- Cardiovascular thrombotic events
- GI bleeding (lower than non-selective NSAIDs)
- Renal impairment, hypertension
Monitoring Parameters
- Blood pressure and renal function
- Cardiovascular risk
- Medication overuse headache
Pregnancy & Lactation
- Avoid at 20 weeks gestation and later; avoid in the third trimester
- Present in milk in small amounts